New Zealand markets closed
  • NZX 50

    11,596.03
    -21.11 (-0.18%)
     
  • NZD/USD

    0.6391
    +0.0011 (+0.18%)
     
  • NZD/EUR

    0.6041
    +0.0005 (+0.09%)
     
  • ALL ORDS

    7,406.30
    +36.90 (+0.50%)
     
  • ASX 200

    7,213.20
    +37.70 (+0.53%)
     
  • OIL

    71.97
    +0.51 (+0.71%)
     
  • GOLD

    1,803.80
    +2.30 (+0.13%)
     
  • NASDAQ

    11,637.50
    +140.10 (+1.22%)
     
  • FTSE

    7,472.17
    -17.02 (-0.23%)
     
  • Dow Jones

    33,781.48
    +183.56 (+0.55%)
     
  • DAX

    14,264.56
    +3.37 (+0.02%)
     
  • Hang Seng

    19,890.96
    +440.73 (+2.27%)
     
  • NIKKEI 225

    27,901.01
    +326.58 (+1.18%)
     
  • NZD/JPY

    87.1480
    +0.0490 (+0.06%)
     

PROMETRIKA Presents Exploring the Impact of Decentralized Clinical Trials – A Live Webcast

Thursday, October 13, 2022, 6:00 -7:00 PM EDT; Cambridge, MA, USA

A look at the benefits and challenges of decentralized clinical trials and the implications for their long-term adoption

CAMBRIDGE, Mass., September 29, 2022--(BUSINESS WIRE)--Join PROMETRIKA and guest Ken Getz, MBA, Executive Director of the Tufts Center for the Study of Drug Development, to explore the ongoing experience with decentralized clinical trials (DCTs). Mr. Getz and Chelsey Ryan, PMP, Director, Clinical Operations and Pharmacovigilance at PROMETRIKA, will review data on DCT use and discuss the types of studies most suited for virtual and remote support. Participants in the live webcast will have the opportunity to discuss with Mr. Getz how to advance DCTs in clinical research.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005619/en/

(Graphic: Business Wire)

Mr. Getz has enjoyed a 30-year career of providing research and information to clinical trial professionals in the drive to understand and improve clinical research. An internationally recognized expert on clinical trial management practices and trends, Mr. Getz’s studies on protocol design complexity, clinical research efficiency and effectiveness, and the global outsourcing landscape have contributed to an industry-wide understanding of these critical markets. His current research aims to inform the adoption of decentralized clinical trials.

Ms. Ryan’s extensive 12-year background in leading global clinical research projects has given her the knowledge and insight to translate the many needs of trial stakeholders into unified goals. As the industry embraces decentralization, Ms. Ryan continues to examine the best application of DCT methods to optimize each clinical trial.

"We have gained first-hand experience during the pandemic with, and we’re learning much more about how to optimize the use of, decentralized clinical trial solutions. I’m very excited to be sharing Tufts CSDD data to inform best DCT use practices ."

Ken Getz, MBA
Executive Director and Research Professor
Tufts CSDD

" We are thrilled to have Ken Getz speak about his in-depth research on decentralized trials. We hope you will join us! The evening promises a robust discussion on the future of clinical research and the role DCTs will play."

Miganush Stepanians, PhD
Founder, President, and CEO
PROMETRIKA, LLC

Link to Register to the Live Webcast: https://pages.services/events.prometrika.com/Live-Webcast-dct-event-page/

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005619/en/

Contacts

For further information please contact
Kathy Zheng
kzheng@prometrika.com